MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

IL-23 inhibition

  • Home
  • IL-23 inhibition
Reversing Epigenetic Aging in Psoriasis: The Impact of Tildrakizumab over 52 Weeks
Posted inDermatology news

Reversing Epigenetic Aging in Psoriasis: The Impact of Tildrakizumab over 52 Weeks

Posted by By MedXY 08/26/2026
This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.
Read More
  • Plasma POMC as a Predictive Biomarker for Silent Corticotroph Adenomas in Non-Functioning Pituitary Tumors
  • TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy
  • Integrated 40-Gene Expression Profile Enhances Prognostic Precision and Guides Adjuvant Radiation in High-Risk Cutaneous Squamous Cell Carcinoma
  • Long-Term Efficacy and Visual Field Outcomes of Selective Laser Trabeculoplasty in Glaucoma Management
  • Post-ICU Frailty in Older Adults Following Septic Shock: Key Predictors and Clinical Implications
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top